Home » Newsletters » BioWorld

BioWorld

Sep. 27, 2000

View Archived Issues

Appointments and Advancements

Immunomedics Begins Phase III Of LymphoCide For Lymphoma

Dynavax Raises $22.6M To Fund Immune Therapies Development

NeoPharm Raises $106M Publicly To Support Oncology Pipeline

Other News To Note

Correction (Article Updated in Database)

PDL Exceeds Expectation With $355M Offering Of 3M Shares

Novartis Dedicates $30M To BioTransplant Joint Venture

Positional Cloning By International Team Finds Susceptibility Gene For Complex Diabetes Mellitus Type II

Cell Therapeutics Gets FDA Approval For Leukemia Drug